Skip to Main content Skip to Navigation
Journal articles

Bystander immunotherapy as a strategy to control allergen-driven airway inflammation.

Abstract : Allergic asthma is a chronic inflammatory disease characterized by airway hyperresponsiveness (AHR), lung infiltration of Th2 cells, and high levels of IgE. To date, allergen-specific immunotherapy (SIT) is the only treatment that effectively alleviates clinical symptoms and has a long-term effect after termination. Unfortunately, SIT is unsuitable for plurisensitized patients, and highly immunogenic allergens cannot be used. To overcome these hurdles, we sought to induce regulatory CD4(+) T cells (Treg) specific to an exogenous antigen that could be later activated as needed in vivo to control allergic responses. We have established an experimental approach in which mice tolerized to ovalbumin (OVA) were sensitized to the Leishmania homolog of receptors for activated c kinase (LACK) antigen, and subsequently challenged with aerosols of LACK alone or LACK and OVA together. Upon OVA administration, AHR and allergic airway responses were strongly reduced. OVA-induced suppression was mediated by CD25(+) Treg, required CTLA-4 and ICOS signaling and resulted in decreased numbers of migrating airway dendritic cells leading to a strong impairment in the proliferation of allergen-specific Th2 cells. Therefore, inducing Treg specific to a therapeutic antigen that could be further activated in vivo may represent a safe and novel curative approach for allergic asthma.Mucosal
Document type :
Journal articles
Complete list of metadata

Cited literature [30 references]  Display  Hide  Download
Contributor : Marie-Hélène Derudas Connect in order to contact the contributor
Submitted on : Friday, February 13, 2015 - 11:16:38 AM
Last modification on : Thursday, August 4, 2022 - 4:57:36 PM
Long-term archiving on: : Sunday, April 16, 2017 - 8:19:20 AM


Navarro-Muc Immunol.pdf
Files produced by the author(s)



Séverine Navarro, Anne Lazzari, Akira Kanda, Sébastien Fleury, David Dombrowicz, et al.. Bystander immunotherapy as a strategy to control allergen-driven airway inflammation.. Mucosal Immunology, Nature Pub. Group, 2015, 8 (4), pp.841-851. ⟨10.1038/mi.2014.115⟩. ⟨inserm-01116372⟩



Record views


Files downloads